| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2012: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2011: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2009: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
|---|
| Research Abstract |
Vancomycin is a clinically used antibacterial against nosocomial infections. However, vancomycin-resistant enterococci (VRE) is now widespread over the world. Moreover, the resistant nature of VRE has been transferred to Staphylococcus aureus, the major nosocomial pathogen. In this study, chemical modifications of vancomycin was conducted to restore its activity to the resistant bacteria. Three major achievements are the following. 1) Cell wall intermediates of vancomycin-resistant bacteria were chemically prepared. It made it possible to examine peptidoglycan biosynthesis in vitro greater in detail. 2) A novel vancomycin modification method using cross-coupling reaction was developed. 3) The active conformation of vancomycin dimers was experimentally suggested.
|
